Here are five things to note:
1. In his new role, Mr. Lyons will drive sales of the company’s silicon nitride implants in the spinal fusion market.
2. With more than 27 years of sales and sales management experience in the medical device field, Mr. Lyons previously held leadership positions at Stryker’s orthopedics division and Zimmer Biomet’s spine division.
3. Amedica also received FDA clearance for its Taurus pedicle screw system.
4. The company plans to conduct a full market launch of the Taurus system this year.
5. Amedica didn’t receive FDA clearance for its Valeo C+CsC, which is a composite spinal fusion device. This device is already marketed in Europe with positive outcomes.
More articles on devices:
Spineway’s capital boosts nearly $1.49M — 5 notes
Reconstructive knee replacement market to reach $5B by 2020 — 5 takeaways
System detects early stages of idiopathic scoliosis with 3D scans: 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
